Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics

Kiniksa Pharmaceuticals, Ltd. - (KNSA): $16.67

-0.38 (-2.23%)

POWR Rating

Component Grades














  • KNSA scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.96% of US stocks.
  • The strongest trend for KNSA is in Momentum, which has been heading up over the past 179 days.
  • KNSA's current lowest rank is in the Stability metric (where it is better than 9.92% of US stocks).

KNSA Stock Summary

  • For KNSA, its debt to operating expenses ratio is greater than that reported by only 8.59% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.28 for KINIKSA PHARMACEUTICALS LTD; that's greater than it is for merely 16.73% of US stocks.
  • As for revenue growth, note that KNSA's revenue has grown 794.19% over the past 12 months; that beats the revenue growth of 98.56% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to KINIKSA PHARMACEUTICALS LTD are HYPR, BHIL, PLSE, VNRX, and NSPR.
  • KNSA's SEC filings can be seen here. And to visit KINIKSA PHARMACEUTICALS LTD's official web site, go to

KNSA Valuation Summary

  • KNSA's EV/EBIT ratio is -29.1; this is 438.37% lower than that of the median Healthcare stock.
  • Over the past 55 months, KNSA's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for KNSA.

Stock Date P/S P/B P/E EV/EBIT
KNSA 2022-11-25 6.2 2.9 7.7 -29.1
KNSA 2022-11-23 6.1 2.8 7.6 -28.7
KNSA 2022-11-22 6.2 2.9 7.7 -29.3
KNSA 2022-11-21 6.3 2.9 7.8 -29.5
KNSA 2022-11-18 6.3 2.9 7.9 -29.8
KNSA 2022-11-17 6.2 2.8 7.7 -29.0

KNSA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KNSA has a Quality Grade of F, ranking ahead of 4.7% of graded US stocks.
  • KNSA's asset turnover comes in at 0.023 -- ranking 364th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows KNSA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.023 0.68 -1.083
2021-03-31 0.000 NA -0.935
2020-12-31 0.000 NA -0.872
2020-09-30 0.000 NA -0.783
2020-06-30 0.000 NA -0.802
2020-03-31 0.000 NA -0.755

KNSA Price Target

For more insight on analysts targets of KNSA, see our KNSA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.00 Average Broker Recommendation 1.3 (Strong Buy)

KNSA Stock Price Chart Interactive Chart >

Price chart for KNSA

KNSA Price/Volume Stats

Current price $16.67 52-week high $17.19
Prev. close $17.05 52-week low $7.36
Day low $16.12 Volume 256,000
Day high $16.90 Avg. volume 332,840
50-day MA $13.89 Dividend yield N/A
200-day MA $11.18 Market Cap 1.16B

Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda

KNSA Latest News Stream

Event/Time News Detail
Loading, please wait...

KNSA Latest Social Stream

Loading social stream, please wait...

View Full KNSA Social Stream

Latest KNSA News From Around the Web

Below are the latest news stories about KINIKSA PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate KNSA as an investment opportunity.

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at A replay of the webcast will also be available on Kiniksa’s website within app

Yahoo | November 23, 2022

Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.

Yahoo | November 10, 2022

Wall Street Analysts Predict a 73% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 72.7% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 7, 2022

Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why

Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Yahoo | November 7, 2022

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (KNSA)

Q3 2022 Earnings Conference Call

November 1, 2022 8:30 AM ET

Company Participants

Rachel Frank – Head-Investor Relations

Sanj K. Patel – Chief Executive Officer

John Paolini – Chief Medical Officer

Ross Moat – Chief Commercial Officer

Mark Ragosa – Chief Financial Officer

Eben Tessari – Chief Operating Officer

Conference Call Participants

Anupam Rama – JPMorgan

Paul Choi – Goldman Sachs

Alex Hammond – Bank of America



Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter Earnings Conference Call. At this time, all participan...

SA Transcripts on Seeking Alpha | November 1, 2022

Read More 'KNSA' Stories Here

KNSA Price Returns

1-mo 19.97%
3-mo N/A
6-mo 92.72%
1-year 40.68%
3-year 67.20%
5-year N/A
YTD 41.63%
2021 -33.39%
2020 59.76%
2019 -60.63%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6518 seconds.